Videos
Considering Triplet Therapy for Nondriver NSCLC
Second-Line Therapy in Extranodal Marginal Zone Lymphoma
Perspective on Treating Advanced Marginal Zone Lymphoma
David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
2
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
3
ctDNA Refines Risk in Neoadjuvant-Resistant Breast Cancer
4
High Survival Seen with Nogapendekin Alfa Inbakicept in Papillary NMIBC
5